Tags

Type your tag names separated by a space and hit enter

Soy isoflavones in the management of postmenopausal osteoporosis.
Menopause. 2008 Jul-Aug; 15(4 Pt 1):748-57.M

Abstract

This is a review article designed to address the effects of soy isoflavones on bone metabolism in postmenopausal women and their place in the prevention and treatment of postmenopausal osteoporosis. Soy isoflavones are natural products that could be used as an alternative to menopausal hormone therapy because they are structurally and functionally related to 17beta-estradiol. In vitro and animal studies have shown that they act in multiple ways to exert their bone-supporting effects. They act on both osteoblasts and osteoclasts through genomic and nongenomic pathways. Epidemiological studies and clinical trials suggest that soy isoflavones have beneficial effects on bone mineral density, bone turnover markers, and bone mechanical strength in postmenopausal women. However, there are conflicting results related to differences in study design, estrogen status of the body, metabolism of isoflavones among individuals, and other dietary factors. The long-term safety of soy isoflavone supplements remains to be demonstrated.

Authors+Show Affiliations

Department of Internal Medicine, Ondokuz Mayis University, Samsun, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18277912

Citation

Atmaca, Aysegul, et al. "Soy Isoflavones in the Management of Postmenopausal Osteoporosis." Menopause (New York, N.Y.), vol. 15, no. 4 Pt 1, 2008, pp. 748-57.
Atmaca A, Kleerekoper M, Bayraktar M, et al. Soy isoflavones in the management of postmenopausal osteoporosis. Menopause. 2008;15(4 Pt 1):748-57.
Atmaca, A., Kleerekoper, M., Bayraktar, M., & Kucuk, O. (2008). Soy isoflavones in the management of postmenopausal osteoporosis. Menopause (New York, N.Y.), 15(4 Pt 1), 748-57. https://doi.org/10.1097/gme.0b013e31815c1e7f
Atmaca A, et al. Soy Isoflavones in the Management of Postmenopausal Osteoporosis. Menopause. 2008 Jul-Aug;15(4 Pt 1):748-57. PubMed PMID: 18277912.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soy isoflavones in the management of postmenopausal osteoporosis. AU - Atmaca,Aysegul, AU - Kleerekoper,Michael, AU - Bayraktar,Miyase, AU - Kucuk,Omer, PY - 2008/2/19/pubmed PY - 2008/9/16/medline PY - 2008/2/19/entrez SP - 748 EP - 57 JF - Menopause (New York, N.Y.) JO - Menopause VL - 15 IS - 4 Pt 1 N2 - This is a review article designed to address the effects of soy isoflavones on bone metabolism in postmenopausal women and their place in the prevention and treatment of postmenopausal osteoporosis. Soy isoflavones are natural products that could be used as an alternative to menopausal hormone therapy because they are structurally and functionally related to 17beta-estradiol. In vitro and animal studies have shown that they act in multiple ways to exert their bone-supporting effects. They act on both osteoblasts and osteoclasts through genomic and nongenomic pathways. Epidemiological studies and clinical trials suggest that soy isoflavones have beneficial effects on bone mineral density, bone turnover markers, and bone mechanical strength in postmenopausal women. However, there are conflicting results related to differences in study design, estrogen status of the body, metabolism of isoflavones among individuals, and other dietary factors. The long-term safety of soy isoflavone supplements remains to be demonstrated. SN - 1072-3714 UR - https://www.unboundmedicine.com/medline/citation/18277912/Soy_isoflavones_in_the_management_of_postmenopausal_osteoporosis_ L2 - https://doi.org/10.1097/gme.0b013e31815c1e7f DB - PRIME DP - Unbound Medicine ER -